Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 13c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St headed for weekly gains as earnings season nears
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $4.57 +0.88%
EPS Growth %: -78.9%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
HOVR, VFS, PGR, More
EPS Growth %: -78.9%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.82), $0.13 worse than the analyst estimate of ($0.69). Revenue for the quarter came in at $51.72 million versus the consensus estimate of $55.04 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $258.2 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Greenland Resources Announces Voting Results
- Citi keeps neutral rating on Helmerich & Payne with $48 target
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
